The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON‐YEARS of observation
Abstract
Objective: To ascertain the relationship between anti–tumor necrosis factor (anti‐TNF) therapy, methotrexate (MTX), and the risk of lymphoma in patients with rheumatoid arthritis (RA). This report updates our previous report during 29,314 person‐years of followup. Methods: Participants in the National Data Bank for Rheumatic Diseases (NDB) longitudinal study of long‐term outcomes of RA completed semiannual questionnaires from 1998 through 2005, during 89,710 person‐years of followup. Lymphoma reports were validated by medical records. The association between lymphoma and treatment was investigated using conditional logistic regression, adjusted for severity and demographic covariates. Results: Of the 19,591 participants, 55.3% received biologic agents and 68.0% received MTX while enrolled in the NDB. The lymphoma incidence rate was 105.9 (95% confidence interval [95% CI] 86.6–129.5) per 100,000 person‐years of exposure. Compared with the SEER (Surveillance, Epidemiology, and End‐Results) lymphoma database, the standardized incidence ratio was 1.8 (95% CI 1.5–2.2). The odds ratio (OR) for lymphoma in patients who received anti‐TNF therapy compared with patients who did not receive anti‐TNF therapy was 1.0 (95% CI 0.6–1.8 [ P = 0.875]). The OR for lymphoma in patients who received anti‐TNF plus MTX therapy compared with patients who received MTX treatment alone was 1.1 (95% CI 0.6–2.0 [ P = 0.710]). Infliximab and etanercept considered individually also were not associated with a risk of lymphoma. Conclusion: In a study of lymphoma in 19,591 RA patients over 89,710 person‐years of followup, which included exposure to anti‐TNF therapy in 10,815 patients, we did not observe evidence for an increase in the incidence of lymphoma among patients who received anti‐TNF therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doody, M. M., Hayes, H. M., & Bilgrad, R. (2001) · Annals of Epidemiology · doi:10.1016/s1047-2797(00)00177-0 · Cited by 79
Cited by
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J., & Lacerda, A. P. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201244 · Cited by 591
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Simon, T. A., Thompson, A., Gandhi, K. K., Hochberg, M. C., & Suissa, S. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0728-9 · Cited by 557
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., & Van Gelder, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.048 · Cited by 483
Metadata
- Authors
- Wolfe, F., & Michaud, K.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-04-27
- Volume
- 56
- Issue
- 5
- Pages
- 1433-1439
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2017281030
- Cited by
- 348
- References
- 1
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON‐YEARS of observation. https://app.cochat.ai/papers/10.1002/art.22579
- The paper
- Wolfe, F., & Michaud, K. (2007). The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON‐YEARS of observation. Arthritis & Rheumatism. https://doi.org/10.1002/art.22579
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.